Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.

Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt LM, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, Bornkamm GW.

Int J Cancer. 2007 Apr 1;120(7):1387-95.

2.

c-MYC impairs immunogenicity of human B cells.

Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.

Adv Cancer Res. 2007;97:167-88. Review.

PMID:
17419945
3.

Regressing nude mouse grafts of Burkitt's lymphoma x lymphoblastoid cell hybrids show deregulation of the c-myc gene and expression of the EBV latent membrane protein.

Wolf J, Klevenz B, Pawlita M, Komitowski D, Moldenhauer G, zur Hausen H.

Int J Cancer. 1991 Jan 2;47(1):99-104.

PMID:
1702406
4.

NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.

Kanda K, Hu HM, Zhang L, Grandchamps J, Boxer LM.

J Biol Chem. 2000 Oct 13;275(41):32338-46.

6.

c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J.

J Virol. 2009 May;83(10):5014-27. doi: 10.1128/JVI.02264-08.

7.

Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.

Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40.

8.

MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Staege MS, Lee SP, Frisan T, Mautner J, Scholz S, Pajic A, Rickinson AB, Masucci MG, Polack A, Bornkamm GW.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4550-5.

9.

Epstein-Barr virus and Burkitt's lymphoma.

Magrath I, Jain V, Bhatia K.

Semin Cancer Biol. 1992 Oct;3(5):285-95.

PMID:
1335792
10.

Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV).

Calender A, Cordier M, Billaud M, Lenoir GM.

Int J Cancer. 1990 Oct 15;46(4):658-63.

PMID:
1698730
11.

c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.

Polack A, Hörtnagel K, Pajic A, Christoph B, Baier B, Falk M, Mautner J, Geltinger C, Bornkamm GW, Kempkes B.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10411-6.

12.

The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.

Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.

Blood. 2009 Sep 17;114(12):2448-58. doi: 10.1182/blood-2008-09-181008.

13.

Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.

Masucci MG, Zhang QJ, Gavioli R, De Campos-Lima PO, Murray RJ, Brooks J, Griffin H, Ploegh H, Rickinson AB.

Int Immunol. 1992 Nov;4(11):1283-92.

PMID:
1282031
15.

Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines.

Baran-Marszak F, Fagard R, Girard B, Camilleri-Broët S, Zeng F, Lenoir GM, Raphaël M, Feuillard J.

Lab Invest. 2002 Nov;82(11):1463-79.

PMID:
12429807
17.

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.

Blood. 1995 Jul 15;86(2):659-65.

18.

Differential effect of heat shock on RNA metabolism in human Burkitt's lymphoma B-cell lines.

Kumar A, Kurl RN, Kryworuchko M, Diaz-Mitoma F, Sharma S.

Leuk Res. 1995 Nov;19(11):831-40.

PMID:
8551800
19.

Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil.

Araujo I, Foss HD, Bittencourt A, Hummel M, Demel G, Mendonca N, Herbst H, Stein H.

Blood. 1996 Jun 15;87(12):5279-86.

20.

The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.

Polack A, Strobl L, Feederle R, Schweizer M, Koch E, Eick D, Wiegand H, Bornkamm GW.

Oncogene. 1991 Nov;6(11):2033-40.

PMID:
1945409
Items per page

Supplemental Content

Support Center